2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Embryo/Fetus, Pediatric, Pregnant, Young Adult
PAPER

1163 Bone turnover biomarkers reveal impaired osteoblast function as a driver of low bone mass in sickle cell disease

Jahnavi Gollamudi, MD, Hong Li, PhD2, Leyla Yamila Teos, PhD3, Oyebimpe Adesina, MD,MS4
1 Division of Hematology, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
2 University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
3 University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
4 University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Introduction:Low bone mineral density (BMD), independent of osteonecrosis, is associated with chronic pain in children and adolescents with sickle cell disease (SCD). The prevalence of low BMD in SCD increases with age: 30% in children (6 to <12 years), 37% in adolescents (12 to <18 years), and 42% in young adults (18 to 24 years). Whether this trajectory of skeletal decline continues to affect clinical outcomes in adulthood and the biological mechanisms involved remain poorly characterized. In our prospective SCD Bone Pain study (NCT05283148), adults with low BMD and osteonecrosis reported worse pain than those with either skeletal complication alone. We hypothesize that dysregulated bone metabolism, inflammation, and abnormal vascular adhesion underlie low BMD in SCD. To test this hypothesis, we evaluated associations between lumbar spine BMD Z-scores and biomarkers of bone turnover, inflammation, and endothelial function among participants in the SCD Bone Pain study.

Methods: We recruited 53 ambulatory adults with SCD from the University of California, Davis, Comprehensive Cancer Center to undergo dual-energy X-ray absorptiometry scans of the lumbar spine, hip, and forearm. We categorized participants with BMD Z-scores ≤ -2 at the lumbar spine or hip as having low BMD. We collected and processed serum samples from each participant and stored them at -80°C for batch analyses. We used commercially available Luminex assays (Millipore Sigma, Burlington, MA) to quantify 47 inflammatory cytokines (e.g., macrophage-derived chemokine (MDC), platelet-derived growth factor-AA (PDGFAA), interleukin (IL)-1α, 1b, 2), 18 bone turnover markers (e.g., Dickkopf-1 (DKK1), osteocalcin (OC), sclerostin (SOST), bone-specific alkaline phosphatase (BSAP)), and 3 vascular adhesion biomarkers (e.g., endothelin-1, soluble (s)P-selectin, sVCAM-1). Given the small sample size and the large number of biomarkers, we used a modified elastic net method for covariate selection to limit collinearity among predictors in the multivariable linear regression model for lumbar spine BMD Z-scores. All data were analyzed using R (version 4.1.3).

Results: Of the 53 SCD Bone Pain study participants, 41 who were not receiving chronic red blood cell exchange transfusions (which can confound biomarker associations) were included in this analysis (61% female, age 38 ± 11.7 years, 59% hemoglobin (Hb) SS/Sβ0 thalassemia). Of these, 18 (44%) had low lumbar spine BMD, and 16 (39%) had radiographically confirmed osteonecrosis. After removing variables with ≥50% missingness, the elastic net method selected biomarkers of bone metabolism (DKK1, SOST, BSAP, and OC) and inflammation (MDC and PDGFAA) for the final multivariable linear regression. Higher DKK1 (pg/mL) and BSAP (µg/mL) levels were associated with lower lumbar spine BMD Z-scores, with β = -0.0005 (p < 0.005) and β = -0.05 (p < 0.05), respectively. Higher MDC (pg/mL) levels were associated with higher lumbar spine BMD Z-scores, with β = +0.002 (p = 0.028). Lumbar spine BMD Z-scores trended positively with SOST and OC and negatively with PDGFAA, though these associations did not reach statistical significance.

Conclusion: We found that dysregulated bone metabolism may contribute to low BMD in SCD. Preclinical studies of humanized SCD mice show heightened osteoclast activity (bone resorption) and blunted osteoblast activity (bone formation). DKK1 dampens wingless and Int-1 (WNT) signaling and suppresses osteoblast differentiation, whereas BSAP increases as a compensatory response to high bone turnover. Our results suggest that concurrent suppression of the Wnt pathway by DKK1 and increased bone remodeling, as indicated by BSAP, may underlie low BMD in SCD. The positive association between MDC, typically elevated in chronic inflammatory states, and lumbar spine BMD contrasts with our hypothesis that inflammation lowers bone mass. MDC has been shown to recruit anti-inflammatory immune cells to dampen excessive bone remodeling and may reflect active repair, though this requires further investigation. The cross-sectional design and small sample size of the parent SCD Bone Pain study preclude causal inference and limit the clinical interpretation of this exploratory study. To clarify these relationships and test whether bisphosphonates normalize bone metabolism and reduce bone pain in SCD, we will analyze longitudinal serum samples from adults receiving alendronate in our ongoing SCD osteonecrosis study (NCT06016634).

Jahnavi Gollamudi, MD: No relevant conflicts of interest to declare.